- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05790694
A Trial of HBM9378 in Healthy Chinese Subjects
March 16, 2023 updated by: Harbour BioMed (Guangzhou) Co. Ltd.
A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Phase I Clinical Study in Healthy Chinese Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of HBM9378 (SKB378) After Subcutaneous Administration.
The objective is to evaluate the safety, tolerability and pharmacokinetic profile of a single subcutaneous injection of HBM9378 (SKB378) at different doses in healthy Chinese subjects.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study will consist of one dose esclation part with a total of 5 dose levels.
The Subjects will be randomized to receive HBM9378 as reflected by the guiding principle for the dose esclation/expansion phase.
Each dose group includes a screening period, a baseline period, an observational period, and a safety follow-up period.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Min Xu, Master
- Phone Number: +86 15198081852
- Email: xm15198081852@163.com
Study Locations
-
-
Chengdu
-
Sichuan, Chengdu, China
- Recruiting
- The Fifth People's Hospital of Chengdu
-
Contact:
- Min Xu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent must be obtained.
- Healthy Chinese male and female subjects aged 18 to 50 years (both included) are enrolled, no clinically significant abnormalities.
- Total body weight ≥45kg at screening, and body mass index(BMI)between 18 and 28 kg/m2 (inclusive).
- Female subjects must meet one of the following criteria for participation in this study: Of non-childbearing potential ;
- Male subjects and female subjects of childbearing potential must use an effective contraceptive method during their participation in this clinical study.
- Can communicate successfully with the investigator and understand and comply with the requirements of this study.
Exclusion Criteria:
- History of relevant allergy/hypersensitivity.
History of any of the following diseases:
- Any clinically significant comorbidity, as judged by the investigator.
- Clinical signs of active infection found at screening.
- Previous malignancy within the past 5 years.
- Acute or chronic bronchospastic disease within the past 3 years.
- Subject who are currently suffering from any medical condition.
- Subjects who have undergone organ transplantation.
- Received immunosuppressive therapy within 6 months prior to randomization.
- Received any biological product within 90 days or 5 half-lives (for other study drugs), whichever is longer, prior to randomization, or participated in another clinical study and received a study drug.
- Received any drug within 4 weeks prior to randomization.
- Subjects who had an immunization within 4 weeks prior to randomization; subjects who are scheduled to have an immunization during the study or within 4 weeks after the end of study.
- Donated or lost 400 mL or more blood, or received transfusion of blood or any blood product within 60 days prior to randomization.
- Subjects who are smokers or have used tobacco or nicotine-containing products within 3 months prior to randomization.
- Subjects who regularly consumed alcohol within 3 months prior to screening, or who had consumed alcohol after screening and before administration.
- Subjects who had been exposed to a tuberculosis (TB) patient within 6 months prior to randomization.
- Subjects who had drug abuse or a positive urine drug screen within 12 months prior to randomization.
- Pregnant or lactating women.
- Positive hepatitis B surface antigen (HBsAg) or hepatitis C antibody test result, or clinically significantly abnormal syphilis serology test result.
- History of immunodeficiency disease, including clinically significantly abnormal HIV antibody test result.
- Clinically significantly abnormal vital signs, physical examination, chest radiography, electrocardiogram , or laboratory tests , as judged by the investigator.
- In the investigator's judgment, may increase the risk to the subject.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HBM9378 (SKB378) Injection
Dose: 20 mg/60 mg/200 mg/600 mg/900 mg Frequency: Once Injection subcutaneously
|
Strength: 225 mg (1.5 mL)/vial
|
Placebo Comparator: Placebo
Dose: 20 mg/60 mg/200 mg/600 mg/900 mg Frequency: Once Injection subcutaneously
|
Strength: 225 mg (1.5 mL)/vial
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Strat of Treatment to end of study (approsimately 160days)
|
Incidence and severity of adverse events
|
Strat of Treatment to end of study (approsimately 160days)
|
Pharmacokinetics-AUC0-last
Time Frame: Strat of Treatment to end of study (approsimately 160days)
|
Area under the concentration-time curve from time 0 to last time point after HBM9378 administration
|
Strat of Treatment to end of study (approsimately 160days)
|
Pharmacokinetics-Tmax
Time Frame: Strat of Treatment to end of study (approsimately 160days)
|
Time to Cmax of HBM9378
|
Strat of Treatment to end of study (approsimately 160days)
|
Pharmacokinetics-Cmax
Time Frame: Strat of Treatment to end of study (approsimately 160days)
|
Maximum observed concentration of HBM9378
|
Strat of Treatment to end of study (approsimately 160days)
|
Pharmacokinetics-CL/F
Time Frame: Strat of Treatment to end of study (approsimately 160days)
|
Apparent clearance of HBM9378
|
Strat of Treatment to end of study (approsimately 160days)
|
Pharmacokinetics-Vd/F
Time Frame: Strat of Treatment to end of study (approsimately 160days)
|
Apparent volume of distribution during terminal phase of HBM9378
|
Strat of Treatment to end of study (approsimately 160days)
|
Pharmacokinetics-T1/2
Time Frame: Strat of Treatment to end of study (approsimately 160days)
|
Terminal elimination half-life of HBM9378
|
Strat of Treatment to end of study (approsimately 160days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity
Time Frame: Strat of Treatment to end of study (approsimately 160days)
|
The percentage of patients with anti-drug antibodies after administration.
|
Strat of Treatment to end of study (approsimately 160days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 26, 2022
Primary Completion (Anticipated)
September 22, 2023
Study Completion (Anticipated)
September 22, 2023
Study Registration Dates
First Submitted
February 27, 2023
First Submitted That Met QC Criteria
March 16, 2023
First Posted (Actual)
March 30, 2023
Study Record Updates
Last Update Posted (Actual)
March 30, 2023
Last Update Submitted That Met QC Criteria
March 16, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 9378.1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Universita di VeronaCompleted
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on HBM9378 (SKB378) Injection
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated
-
National Taiwan University HospitalCompleted
-
Royan InstituteCompletedMyocardial InfarctionIran, Islamic Republic of